title: [ORIGINAL PERFORMANCE OF THE INTEGRATED CIRCUITS NEUROPROTECTIVE LECHNIYA ANTERIOR ISCHEMIC OPTIC NEUROPATHY DEPENDING ON BLOOD PRESSURE].
abstract: Anterior ischemic optic neuropathy (AION) is one of the main reasons of vision disorders among middle-aged and elderly people. During the examination of patients with AION, we were interested by the fact of low efficiency of the standard treatment course. Moreover, over 60% of such patients underwent the development of AION on the other eye during 1 year after the beginning of the disease. The purpose of the given study is the development of efficient and original neuroprotection treatment scheme for AION, depending on the arterial pressure rate. We examined 58 patients (65 eyes) with AION, depending on the arterial pressure rate. The patients were divided into two clinical groups. For the first group of 38 patients (38 eyes), we used the original AION treatment scheme developed by us. The group was divided into 3 subgroups, depending on their arterial pressure rate: patients with normal ap., patients with hypertension of I-II stages and patients with hypotension. For the control group, the standard treatment scheme was used. The results received allow us to make a conclusion that the original treatment scheme, developed by us, is more efficient, and it can be recommended as a neuroprotection treatment scheme for AION among the patients with arterial hypertension of I-II stages.
authors.affiliation: Kharkiv National Medical University; State Higher Educational Institution "Ukrainian Academy of Medical Dental", Poltava, Ukraine.
authors.forename: P
authors.initials: P
authors.lastname: Bezdetko
authors.affiliation: Kharkiv National Medical University; State Higher Educational Institution "Ukrainian Academy of Medical Dental", Poltava, Ukraine.
authors.forename: D
authors.initials: D
authors.lastname: Martynyuk
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D007429:Intraocular Pressure; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018917:Optic Neuropathy, Ischemic / Q000188:drug therapy* / Q000503:physiopathology; D010455:Peptides / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D000925:Anticoagulants; D000959:Antihypertensive Agents; D000975:Antioxidants; D036341:Intercellular Signaling Peptides and Proteins; D018696:Neuroprotective Agents; D010455:Peptides; D016194:Receptors, N-Methyl-D-Aspartate; C056590:cortexin